estatinas, doenças cardiovasculares

National Institute for Health and Care Excellence

(NICE). Lipid modification: cardiovascular risk assessment

and the modification of blood lipids for the primary

and secondary prevention of cardiovascular disease.

NICE clinical guideline 67. March 2010.

Taylor F, Huffman MD, Macedo AF, Moore THM,

Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for

the primary prevention of cardiovascular disease. Cochrane

Database of Systematic Reviews 2013, Issue 1.

Art. No.: CD004816. DOI: 10.1002/14651858.CD004816.

pub5.

Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri

D. Primary prevention of cardiovascular mortality and

events with statin treatments: a network meta-analysis

involving more than 65,000 patients. J Am Coll Cardiol.

; 52(22):1769-1781.

Tonelli M, Lloyd A, Clement F, Conly J, Husereau

D, Hemmelgarn B, et al. Efficacy of statins for primary

prevention in people at low cardiovascular risk: a metaanalysis.

CMAJ 2011; 183(16):E1189-E1202.

Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW,

Ford I, et al. Statins and all-cause mortality in high-risk

primary prevention: a meta-analysis of 11 randomized

controlled trials involving 65229 participants Arch Intern

Med. 2010; 170(12):1024-1031.

Thavendiranathan P, Bagai A, Brookhart MA,

Choudhry NK. Primary prevention of cardiovascular

diseases with statin therapy. Arch Intern Med 2006;

(21):2307-2313.

Cholesterol Treatment Trialists’ (CTT) Collaborators,

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J,

et al.. The effect of lowering LDL cholesterol with statin

therapy in people at low risk of vascular disease: metaanalysis

of individual data from 27 randomised trials.

Lancet 2012; 380(9841):581-590.